Clinical Trials Logo

Filter by:
NCT ID: NCT05467904 Not yet recruiting - Clinical trials for Post-acute COVID-19 Syndrome

Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID

Start date: June 2024
Phase: N/A
Study type: Interventional

This is a double-blind, randomized, placebo-controlled single-center clinical trial to explore the safety and efficacy of a full cannabis flower formulation, rich in cannabinoids and terpenes formulation, Xltran Plus™ and Xltran™, both compared to placebo for the treatment of Long COVID patients with prolonged symptoms caused by COVID-19.

NCT ID: NCT05467748 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tazemetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.

NCT ID: NCT05467592 Not yet recruiting - Knee Osteoarthritis Clinical Trials

Central Sensitization in Patients Seeking Outpatient Physical Therapy Services

Start date: July 18, 2022
Phase:
Study type: Observational

This is an observational study to examine presence of CS in patients with knee osteoarthritis (OA), chronic LBP (CLBP), and chronic neck pain (CNP) seeking outpatient physical therapy (PT) services. The study will also examine if outcomes differ between patients with CS and patients without CS symptoms with standard PT interventions.

NCT ID: NCT05467228 Not yet recruiting - Laryngeal Dystonia Clinical Trials

Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia

Start date: January 1, 2025
Phase: Phase 2
Study type: Interventional

The general aim of the research is to provide scientific evidence that vibro-tactile stimulation (VTS) represents a non-invasive form of neuromodulation that can induce measurable improvements in the speech of patients with laryngeal dystonia (LD) - also called spasmodic dysphonia (SD).

NCT ID: NCT05466929 Not yet recruiting - Mental Health Clinical Trials

Engagement With Digital Mental Health (DMH) Technologies in Pediatric Primary Care

TeACH
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this study is to use and adapt existing digital mental health technologies to advance the engagement, assessment, detection, treatment, and delivery of services for pediatric mental health. Specifically, user-centered design methodologies and an implementation science framework will be used to guide the development and implementation of the Teen Assess, Check, and Heal (TeACH) System into a pediatric primary care clinic serving teens and families from underserved communities. Study objectives include: 1. Collaborating with underserved teens and their parents to identify strategies to target top barriers to engagement as well as top ethical concerns and requirements for cultural relevance, usability, and usefulness of the TeACH System (Phase 1) 2. Refining the plan for implementing the TeACH System through observations, interviews, and co-design workshops with pediatric primary care pediatricians and staff (Phase 2), and 3. Implementing the TeACH System into a primary care clinics and evaluating it in a randomized trial. (Phase 3) The team will measure engagement outcomes and satisfaction with the TeACH System.

NCT ID: NCT05464940 Not yet recruiting - Atrial Fibrillation Clinical Trials

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

Start date: June 2023
Phase: N/A
Study type: Interventional

This "How caffeine Induces Atrial Tachyarrhythmias" trial will be a multi-center, randomized, double-blinded trial of intravenous caffeine versus placebo among patients undergoing pulmonary vein isolation procedures for Atrial Fibrillation(AF).

NCT ID: NCT05464511 Not yet recruiting - Stroke Clinical Trials

Impact of Steerable Delivery Sheaths on Successful Closure of LA A With AMULET

Start date: April 2023
Phase: N/A
Study type: Interventional

The novel Amplatzer steerable delivery sheath (Abbott Vascular) is found to be safe and effective in performing LAAO procedure. However, the procedural outcomes have not been compared with the traditional non-steerable fixed curve sheath. In this study investigators aim to compare the outcome of patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using non-steerable fixed curve sheath versus a novel steerable sheath.

NCT ID: NCT05458960 Not yet recruiting - Cervical Cancer Clinical Trials

Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate

BASICS
Start date: July 31, 2024
Phase: N/A
Study type: Interventional

The investigators will perform a randomized controlled trial in which 72 eligible patients (low-income, uninsured, or on Medicaid) who are referred for colposcopy at Washington University School of Medicine, are enrolled and then screened for unmet social needs and distress. The participants will then be randomized 1:1 into either receive the social needs navigator program (n=36) or enhanced usual care (n=36).

NCT ID: NCT05457972 Not yet recruiting - Breastfeeding Clinical Trials

Postpartum Vaginal Estrogen for Breastfeeding Patients

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

Sexual dysfunction is very common in the postpartum period and is more common in people who breastfeed or pump. This research study was designed to help determine whether postpartum patients who use vaginal estrogen cream while breastfeeding have improved sexual function compared to postpartum patients who do not.

NCT ID: NCT05457959 Not yet recruiting - Clinical trials for Diffuse Hemispheric Glioma, H3 G34-Mutant

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Start date: December 1, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial tests peptide-pulsed dendritic cell vaccination in combination with immunotherapy nivolumab and ipilimumab for the treatment diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Together, the vaccine and immunotherapy drugs given before and after surgical resection (the removal of tumor cells through surgery) may improve stimulation of anti-tumor immunity to help fight the cancer.